Your browser is no longer supported. Please, upgrade your browser.
Enlivex Therapeutics Ltd.
Index- P/E- EPS (ttm)-0.86 Insider Own24.65% Shs Outstand14.37M Perf Week-15.27%
Market Cap175.46M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float9.83M Perf Month-17.15%
Income-11.80M PEG- EPS next Q-0.21 Inst Own10.70% Short Float0.68% Perf Quarter-57.97%
Sales- P/S- EPS this Y19.00% Inst Trans3.04% Short Ratio0.27 Perf Half Y-17.64%
Book/sh2.47 P/B3.93 EPS next Y- ROA-32.20% Target Price- Perf Year85.31%
Cash/sh1.98 P/C4.91 EPS next 5Y- ROE-37.50% 52W Range4.49 - 29.40 Perf YTD15.18%
Dividend- P/FCF- EPS past 5Y53.90% ROI- 52W High-66.97% Beta1.08
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low116.26% ATR0.78
Employees50 Current Ratio8.70 Sales Q/Q- Oper. Margin- RSI (14)38.87 Volatility7.57% 7.31%
OptionableYes Debt/Eq0.00 EPS Q/Q-37.20% Profit Margin- Rel Volume0.17 Prev Close10.04
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume246.99K Price9.71
Recom- SMA20-9.18% SMA50-17.99% SMA200-5.80% Volume69,419 Change-3.29%
Mar-02-21Reiterated H.C. Wainwright Buy $22 → $33
Mar-22-21 08:00AM  
Mar-09-21 08:00AM  
Mar-08-21 08:00AM  
Mar-01-21 07:55AM  
Feb-22-21 08:00AM  
Feb-18-21 08:00AM  
Feb-16-21 08:30AM  
Feb-12-21 05:21PM  
Feb-09-21 11:25PM  
Feb-03-21 12:34PM  
Jan-11-21 08:00AM  
Dec-31-20 12:46AM  
Dec-21-20 08:00AM  
Dec-09-20 01:10PM  
Dec-07-20 08:00AM  
Dec-03-20 01:09PM  
Nov-18-20 08:00AM  
Nov-17-20 08:18AM  
Nov-11-20 08:14AM  
Nov-05-20 08:30AM  
Nov-03-20 01:44PM  
Oct-27-20 08:00AM  
Oct-22-20 08:45AM  
Oct-13-20 09:28AM  
Oct-02-20 09:16AM  
Oct-01-20 04:31PM  
Sep-16-20 08:00AM  
Aug-25-20 08:00AM  
Aug-10-20 08:00AM  
Jul-20-20 08:20AM  
Jun-18-20 08:30AM  
Jun-01-20 08:00AM  
May-28-20 08:30AM  
May-20-20 06:56AM  
May-07-20 08:00AM  
Apr-13-20 08:25AM  
Mar-18-20 08:00AM  
Mar-09-20 08:13AM  
Mar-05-20 08:15AM  
Mar-03-20 08:53AM  
Mar-02-20 08:00AM  
Feb-26-20 01:46PM  
Feb-25-20 03:25PM  
Feb-24-20 01:54PM  
Feb-20-20 08:38AM  
Nov-21-19 07:30AM  
Nov-20-19 04:14PM  
Nov-18-19 08:30AM  
Nov-12-19 07:30AM  
Nov-05-19 08:42AM  
Nov-04-19 07:30AM  
Oct-30-19 11:55AM  
Oct-24-19 07:30AM  
Oct-10-19 07:30AM  
Oct-08-19 07:30AM  
Oct-07-19 07:30AM  
Sep-23-19 07:30AM  
Sep-09-19 07:30AM  
Sep-04-19 07:30AM  
Aug-19-19 07:30AM  
Aug-01-19 03:50PM  
Jul-16-19 07:30AM  
Jun-18-19 07:30AM  
Jun-06-19 07:30AM  
May-30-19 08:35AM  
Apr-18-19 08:15AM  
Apr-08-19 07:30AM  
Apr-04-19 09:31AM  
Mar-26-19 07:30AM  
Enlivex Therapeutics Ltd. operates as a clinical stage immunotherapy company. It is developing Allocetra, an off-the-shelf cell therapy designed to reprogram macrophages into homeostatic state. Resetting non-homeostatic macrophages into homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. Diseases, such as solid cancers, sepsis, COVID-19, and others reprogram macrophages out of homeostatic state. Its Allocetra has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents. The company has a research collaboration with Yale Cancer Center for the assessment of Allocetra to enhance the activity of checkpoint inhibitors in solid tumors. Enlivex Therapeutics Ltd. was incorporated in 2005 and is headquartered in Nes Ziona, Israel.